Bayer’s (BAYRY) treatment of gastrointestinal infections caused by hookworm, emodepside, was granted FDA orphan designation, according to a post to the agency’s site.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer AG’s Observational Study on Vericiguat: A Real-World Insight into Heart Failure Treatment
- Bayer’s New Study on Mirena: A Game Changer for Women’s Health?
- Bayer’s Pioneering Study on 225Ac-PSMA-Trillium for Advanced Prostate Cancer: A Potential Game Changer?
- Bayer’s Darolutamide Study: Real-World Insights into Prostate Cancer Treatment
- Bayer’s FINE-REAL Study: Real-World Insights into Finerenone Use